Extensive early apoptosis in frozen-thawed CD34-positive stem cells decreases threshold doses for haematological recovery after autologous peripheral blood progenitor cell transplantation

Bone Marrow Transplantation

Volumn 29, Issue 3, 2002, Pages 249-255

  de Boer, F ^a   Drager A M ^a   Pinedo, H M ^a   Kessler, F L ^a   van der Wall, E ^a   Jonkhoff, A R ^a   van der Lelie, J ^b   Huijgens, P C ^a   Ossenkoppele, G J ^a   Schuurhuis, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Apoptosis; CD34+; Stem cell transplant; Syto16

Indexed keywords

CARMUSTINE; CD34 ANTIGEN; CELL MARKER; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MYELOABLATIVE AGENT; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE SULFATE;

APOPTOSIS; ARTICLE; AUTOTRANSPLANTATION; CELL ASSAY; CELL MEMBRANE PERMEABILITY; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; FREEZING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; LEUKAPHERESIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; THAWING; VITAL STAIN;

ANTIGENS, CD34; APOPTOSIS; CELL COUNT; CELL SURVIVAL; CRYOPRESERVATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKAPHERESIS; LYMPHOMA, NON-HODGKIN; REAGENT KITS, DIAGNOSTIC; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 85047699482     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703357     Document Type: Article

References (32)

1. Application of whole blood and peripheral blood progenitor cells (PBPC) and new strategies for rescue after intensive cyclic chemotherapy in high-risk breast cancer
2. Mobilization of peripheral blood progenitor cells (PBPC) through a combination of chemotherapy and G-CSF in breast cancer patients and a possibility of unprocessed whole blood collection
3. Double high-dose therapy for Hodgkin’s disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation
4. + cell dose
5. Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancer
6. Toxicities after peripheral blood progenitor cell transplantation for lymphoid malignancies: Analysis of 300 cases in a single institution
7. Adverse events occurring during bone marrow or peripheral blood progenitor cell infusion: Analysis of 126 cases
8. Highdose melphalan with re-infusion of unprocessed, G-CSF-primed whole blood is effective and non-toxic therapy in multiple myeloma
9. Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: A randomized phase II trial in small-cell lung cancer patients
10. Autotransplantation for relapsed, refractory or high risk lymphoma with non cryopreserved hematopoietic peripheral stem cells
11. G-CSF (filgrastim)-stimulated whole blood kept unprocessed at 4°C does support a BEAM-like regimen in bad-risk lymphoma
12. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis
13. Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer
14. Non-cryopreserved unmanipulated hematopoietic peripheral blood stem cell autotransplant program: Long-term results
15. Filgrastim-mobilized peripheral-blood stem cells can be stored at 4 degrees and used in autografts to rescue high-dose chemotherapy
16. Non-cryopreserved, limited number (1 or 2) peripheral blood progenitor cell (PBPC) collections following GCSF administration provide adequate hematologic support for high dose chemotherapy
17. + peripheral blood progenitor cell dose on hematopoietic recovery
18. + L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation
19. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy
20. + cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation
21. BEAM + autologous stem cell transplantation in malignant lymphoma: 100 consecutive transplants in a single centre. Efficacy, toxicity and engraftment in relation to stem-cell source and previous treatment
22. Large populations of non-clonogenic early apoptotic CD34-positive cells are present in frozen-thawed peripheral blood stem cell transplants
23. + cell determination by flow cytometry
24. Viability of haemopoietic progenitors from whole blood, bone marrow and leukapheresis product: Effects of storage media, temperature and time
25. Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support
26. High-dose melphalan followed by autograft employing non-cryopreserved peripheral blood progenitor cells in children
27. Peripheral blood stem cell transplantation-what do we infuse?
28. Flow cytometric analysis of live cell proliferation and phenotype in populations with low viability
29. Flow cytometry using annexin V can detect early apoptosis in peripheral blood stem cell harvests from patients with leukaemia and lymphoma
30. + selection of hematopoietic blood cell collections and autotransplantation in lymphoma: Overnight storage of cells at 4°C does not affect outcome
31. Storage of noncryop-reserved periphered blood stem cells for transplantation
32. + cells in adhesion molecule expression